$3.99
+0.04 (+1.01%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where GNPX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
4 interventional
Held by 0 tracked-famous managers · FINRA short interest 1.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on OsimertinibNCT04486833Recommended Phase 2 Dose (RP2D) - Phase 1Randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Biological: quaratusugene ozeplasmid · Drug: osimertinib, Platinum-Based Chemotherapy | Carcinoma, Non-Small Cell Lung | 158 | Mar 2028 | ≤ 589 d | 2026-01-21 |
| Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC PatientsNCT05703971Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) - Phase 1Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Biological: quaratusugene ozeplasmid, atezolizumab | Small Cell Lung Cancer Extensive Stage | 62 | Jun 2026 | — | 2026-06-03 |
| Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung CancerNCT05062980Recommended Phase 2 Dose (RP2D) - Phase 1Randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Enrollment was slow, due to competition with the many other clinical trials for the same patient population, which led to the decision to end enrollment in the trial. | Biological: quaratusugene ozeplasmid · Drug: pembrolizumab, docetaxel, ramucirumab, Investigator's Treatment of Choice | Non Small Cell Lung Cancer | 5 | 2025-02-03actual | — | 2026-06-03 |
| TUSC2-nanoparticles and Erlotinib in Stage IV Lung CancerNCT01455389Maximum Tolerated Dose (MTD) Level for Drug Treatment CombinationOpen-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Trial terminated by sponsor after decision to evaluate combination of quaratusugene ozeplasmid and osimertinib instead of further evaluating quaratusugene ozeplasmid and erlotinib. | Drug: DOTAP:Chol-TUSC2, Erlotinib, Dexamethasone, Diphenhydramine | Lung Cancer | 25 | 2016-10-27actual | — | 2022-03-02 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19